

## Evaluation of the ACQUITY UPLC H-Class System with ACQUITY QDa Mass Detector for the Determination of Amphetamine, Methamphetamine, Ketamine, and Norketamine in Human Urine for Forensic Toxicology

Nayan S. Mistry, Rob Lee, and Michelle Wood  
Waters Corporation, Wilmslow, UK



### GOAL

To assess the feasibility of using the Waters™ ACQUITY™ UPLC™ H-Class System with the ACQUITY QDa™ Mass Detector (Figure 1) as an alternate technique to immunoassay for illicit drug analysis and quantification.

### BACKGROUND

Amphetamines (methamphetamine and amphetamine) are among the most commonly abused illicit substances in the world. In 2016, it was estimated that around 35 million adults worldwide used amphetamines.<sup>1</sup> The region with the highest annual use was North America at approximately 2% of the population. In the last few years however, there also appears to be a marked increase in consumption within other geographies, particularly East and Southeast Asia, where the amphetamines have been identified as one of the most worrying threats of drug use. Moreover, a rise in the use of Ecstasy (3,4 methylenedioxymethamphetamine; MDMA) in West Asia has been noted, though it is estimated that less than half of the tablets purported to be Ecstasy, truly contain MDMA, but are commonly found to contain methamphetamine, amphetamine, or ketamine.<sup>2</sup>

The ACQUITY QDa Mass Detector has demonstrated great promise as an alternative technique to immunoassay.



Figure 1. The ACQUITY UPLC H-Class System and ACQUITY QDa Mass Detector.

Forensic laboratories often utilize immunoassay for routine urine analysis. While the technique is rapid and simple, there can be some disadvantages, often associated with poor selectivity for example, false positive results for amphetamine or ketamine have been reported for a variety of substances.<sup>3-5</sup> As most positive immunoassay results require a confirmatory test (such as GC or LC-MS), the consequence of false positive identifications, as a result of poor assay selectivity, can significantly compromise laboratory efficiency.

The purpose of this study was to evaluate the UPLC-QDa system as an alternate analytical technique for the analysis of two commonly abused drug classes. This technique uses chromatographic separation coupled with a simple mass detector to address the issues of cross-reactivity and laboratory inefficiencies associated with immunoassay.

Compound	Retention time (min)	Precursor and product ions (m/z)	Deuterated internal standards	Retention time (min)	Precursor and product ion (m/z)
Amphetamine	0.85	<b>136.1</b>	Amphetamine - D11	0.82	<b>147.2</b>
		91.1			98.1
		119.1			
Methamphetamine	1.03	<b>150.1</b>	Methamphetamine - D14	0.99	<b>164.2</b>
		91.1			98.1
		119.1			
Ketamine	1.60	<b>238.1</b>	Ketamine - D4	1.60	<b>242.1</b>
		125.0			129.0
		179.1			
Norketamine	1.50	<b>224.1</b>	Norketamine - D4	1.50	<b>228.1</b>
		125.0			129.0
		207.1			

Table 1: Analytes and corresponding ISTDs together with target ion(s). Precursor ion is indicated in bold font.

## THE SOLUTION

### Materials and experimental

Certified reference standards (1 mg/mL) and their corresponding deuterated internal standards (ISTDs) (100 µg/mL) were purchased from Sigma-Aldrich (Poole, UK; Table 1). A commercial quality control (QC) urine sample (Medidrug® WDT Confirm U, -25% cutoff; p/n: 27UQ01KE) containing amphetamine, methamphetamine, and ketamine at 150 ng/mL was purchased from Medichem (Germany). Authentic drug-free urine samples were collected from volunteers and pooled.

To evaluate analytical selectivity and linearity, a series of calibrators ranging from 40 to 2000 ng/mL, were prepared by spiking mixed reference standards into the pooled drug-free urine. A series of in-house QCs (75, 150, 600, and 1600 ng/mL) were prepared from a separate batch of reference material in pooled urine.

Prior to analysis, all samples and QCs were diluted 5-fold in an aqueous solution containing the ISTDs at a concentration of 500 ng/mL.

Chromatographic separation was achieved using a fast 3 min gradient elution on an ACQUITY UPLC BEH C<sub>18</sub>, 1.7 µm, 2.1 × 50 mm Column (p/n: [186002350](#)) coupled with an ACQUITY UPLC BEH C<sub>18</sub>, 1.7 µm, 2.1 × 5 mm VanGuard™ Pre-Column (p/n: [186003975](#)) on the ACQUITY UPLC H-Class System. Data were acquired with the ACQUITY




Figure 2: Example of response for ketamine prepared in urine. All compounds were quantified by reference to their ISTDs. Data shows replicate analyses for each calibrator (n=3, -X-) and QC (n=15, -◆-).

QDa Mass Detector in positive ionization mode applying selected ion recording (SIR). In-source collision-induced dissociation (CID) was applied at specific cone voltages to generate at least one product ion.<sup>6,7</sup>

## RESULTS

Data were acquired using MassLynx™ Software and processed using the TargetLynx™ Application Manager. The following criteria were used for a positive identification: presence of the precursor ion together with the product ion(s) at the expected retention time (±0.2 min) and with an ion ratio of ±20% of the expected value. Reference ion ratios were based on the ratio of peak-area response of the precursor to the response of the associated product ion(s), and were calculated from the average obtained across the four QC concentrations.

All compounds demonstrated good linearity across the concentration range investigated (40–2000 ng/mL); Figure 2 shows an example of the response for ketamine.

The analysis of the commercial urine QC (WDT -25%) showed the successful identification and the calculated concentrations for amphetamine, methamphetamine, and ketamine were within 12% of expected concentrations.

To assess the effect of some common analytes that are known to interfere with the amphetamine or ketamine immunoassays, 21 substances (Table 2) were selected for investigation. Blank urine was spiked individually with each of the 21 standards at a concentration of 10,000 ng/mL. None of the investigated analytes resulted in a false positive result for amphetamine, methamphetamine, ketamine, and norketamine. In addition, the potential interference was investigated by spiking a QC urine (600 ng/mL) with the same analytes – the results showed no interference in terms of quantitative data.

A selection of authentic urine samples, previously characterized using an established high resolution mass spectrometry screening technique based on the Xevo™ G2-XS QToF, were tested.<sup>8</sup> The results showed good agreement between the two approaches.

## SUMMARY

Drug testing facilities face a perpetual struggle to provide rapid and accurate results. The purpose of this study was to evaluate the ACQUITY UPLC H-Class/ACQUITY QDa System as an alternate technique to potentially replace two commonly applied immunoassays by developing a single, fast analytical method which incorporates a simple sample preparation procedure. Selectivity is achieved by monitoring retention time, precursor and product ion(s), and ion ratios. The method also comprised an analytical range which extended to 2000 ng/mL, offering the user an ability to quantify.

Brompheniramine	MDEA	Phentermine
Buflomedil	MDMA	Phenylpropanolamine
Bupropion	MDA	Propranolol
Chloroquine	Mebeverine	Pseudoephedrine
Ephedrine	Methoxetamine*	Quetiapine*
Fluoxetine	PCP*	Ranitidine
Labetalol	Phenmetrazine	Trazadone

Table 2: Selected number of substances reported to cross-react with amphetamine and ketamine\* immunoassays.<sup>3-5</sup>

Although LC-MS/MS is now established for illicit drug screening and quantification, in forensic toxicology laboratories worldwide, this study shows that for some applications, a single quadrupole-based detector can provide sufficient analytical sensitivity and dynamic range. The ACQUITY QDa Mass Detector has demonstrated great promise as an alternative technique to immunoassay.

## References

1. United Nations Office on Drug and Crimes. World Drug Report 2018. Global Overview of Drug Demand and Supply, Latest trends, cross-cutting issues. [https://www.unodc.org/wdr2018/prelaunch/WDR18\\_Booklet\\_2\\_GLOBAL.pdf](https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_2_GLOBAL.pdf), last accessed Dec 2018.
2. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report, Trends and Developments. [http://www.emcdda.europa.eu/system/files/publications/8585/20181816\\_TDAT18001ENN\\_PDF.pdf](http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf), 2018.
3. Saitman, A.; Park, H.; Fitzgerald, R.L. False-Positive Interference of Common Urine Drug Screen Immunoassays: A Review. *J. Anal. Toxicol.* **2014**, *38*, 387–396.
4. Marin, S.J.; Doyle, K.; Chang, A.; Concheiro-Guisan, M.; Huestis, M.A.; Johnson-Davis, K.L. One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. *J. Anal. Toxicol.* **2016**, *40*(1), 37–42.
5. Chun-Hao, L.; Hsin-Yao, W.; Shin-Heng, S.; Yu-Wen, C. False Positive Ketamine Urine Immunoassay Screen Result Induced by Quetiapine: A Case Report: *J. of the Formosan Medical Association.* **2017**, *116*(9), 1–3.
6. Goshawk, J.; Lee, R.; Wood, M. Evaluation of the Potential of the ACQUITY QDa Mass Detector for Use in Forensic Chemistry and Drug Control Laboratories. *Waters Technology Brief 720006004EN*, May 2017.
7. Lee, R.; Wood, M. Systematic Toxicological Screening Using the ACQUITY UPLC I-Class/Xevo TQ-S micro. *Waters Technology Brief 720005661EN*, March 2016.
8. Waters Corporation. (2014). Forensic Toxicology Screening Application Solution with UNIFI [Brochure]. Milford, MA.

**For Forensic Toxicology Use Only.**

# Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

Waters, The Science of What's Possible, Empower, ACQUITY, UPLC, MassLynx, QDa, VanGuard, and Xevo are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.